The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life and Investigate What This Means to You
NCT ID: NCT03079375
Last Updated: 2019-12-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1499 participants
INTERVENTIONAL
2013-09-01
2015-10-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is well known that the transfer of a patient from hospital to the general practitioner is related with mistakes in the medication of the patient. A report from 2006 measure the number of drug related admissions in Denmark to be 69.000 to 162.000 per year. To reduce these mistakes, more and better communication between the health professionals are suggested. Furthermore medication reviews made by pharmacist seems to reduce the number of drug related readmissions and other drug related issues, which can lead to an economic cost reduction.
Objective
The aim of this study is to investigate the impact of medication review and better communication between the health professionals after discharge of a patient from hospital to the general practitioner. The effect is measured as reducing the number of readmissions and number of visits at the emergency department 30 days and six month after inclusion of the patient.
Method
This study was estimated to include 1500 participants. The patients were randomized to one of three groups; usual care, basic intervention or extended intervention. The usual care received the normal care following the Danish standard procedure. The basic intervention had a medication review by a clinical pharmacist during admission.
The extended interventions group was similar to the basic intervention group plus follow-up with the patient, the general practitioner and if relevant the nursing home and pharmacy one week and six month after discharge by interview with the clinical pharmacist.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Telephone Contact Between Hospital and General Practitioner About Medication Review for Older Patients
NCT03369652
Effect of Pharmacist Provided Drug Information Services After Hospital Discharge
NCT03829995
Self-administration of Patients Own Drugs During Hospital Stay
NCT03541421
Prioritising Patient Medication Review: Hospitals Reaching Out
NCT06451692
Oslo Pharmacist Intervention Study - Effect on Readmissions
NCT02336113
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Pharmacist intervention:
Usual care group: the patients received no intervention by the clinical pharmacist.
Basic intervention group: A structured, patient centered medication review (MR) was conducted by the clinical pharmacist. The following was considered during MR: Were there untreated diagnoses, has the goal of treatment been reached, was the treatment compliant with current national guidelines regarding dose, choice of drug and time of treatment. Focus was at certain drugs most commonly implicated in causing admission. Furthermore, all drugs on the medication list were assessed according to the following: Indication for treatment, drug dose, considering i.e. kidney insufficiency, age, etc., adverse drug events, therapeutic duplication, dosage time and interval, drug formulation and strength, interactions, contraindications, precautions and specific patient characteristics.
Advice on drug selection, dosages, monitoring needs and possibly side effects were given to the physician in charge of the patient, and written in the electronic patient journal (EPJ).
Extended intervention group: MR was conducted according to the same terms and conditions as for the basic intervention group. Upon discharge medication reconciliation was conducted. The pharmacist provided a motivational interview (MI)-based patient interview including a comprehensive summary of changes in the drug therapy during the hospitalization.
Post discharge any drug related problem not dealt with during hospitalization was mailed or faxed to the general practitioner (GP). When needed, the GP, care giver and primary care pharmacy were contacted by phone (approximately five working days after discharge).
Follow-up interview by phone was performed twice. The first was conducted one week post discharge and the second six months after discharge. When needed additional follow-ups could be made. The follow-up interviews had an motivational interview approach.
All interventions were conducted according to a defined standard operating procedure and all interventions were performed by qualified clinical pharmacists from the involved sites. In order to minimize the risk of cultural differences and variations in routine's the regions in between, all data pharmacists were trained prior to entering the study.
Data was analysed after the intention-to-treat method. Data was analyzed after a proportional hazard cox regression with the randomization group as the only variable.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
usual care
no pharmaceutical intervention.
No interventions assigned to this group
basic intervention
Medication review
basic intervention
medication review
extended intervention
medication review, medication interview before discharge and follow-up with patient, GP and if relevant pharmacy and nursing home.
extended intervention
medication review, medication interview before discharge and follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
basic intervention
medication review
extended intervention
medication review, medication interview before discharge and follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Speak and understand Danish
* Admitted via the Acute Medicine Admission Ward
* Are able to give informed consent
Exclusion Criteria
* Declared terminal
* Suicidal
* In custody
* Isolated at the hospital
* Im- and/or expressive aphasia
* Severe dementia
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Hospitals Pharmacies' and Amgros' Research Development Foundation
UNKNOWN
University of Southern Denmark
OTHER
Two public Regional foundations
UNKNOWN
The Actavis Foundation
UNKNOWN
Lene V. Ravn-Nielsen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lene V. Ravn-Nielsen
Clinical pharmacist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lene V. Ravn-Nielsen, M.Sc.Pharm
Role: STUDY_DIRECTOR
Hospital Pharmacy of Funen
References
Explore related publications, articles, or registry entries linked to this study.
Ravn-Nielsen LV, Duckert ML, Lund ML, Henriksen JP, Nielsen ML, Eriksen CS, Buck TC, Pottegard A, Hansen MR, Hallas J. Effect of an In-Hospital Multifaceted Clinical Pharmacist Intervention on the Risk of Readmission: A Randomized Clinical Trial. JAMA Intern Med. 2018 Mar 1;178(3):375-382. doi: 10.1001/jamainternmed.2017.8274.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Cross-sectorial medicine
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.